

Maria Zambon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6653194/publications.pdf>

Version: 2024-02-01

195
papers

26,380
citations

18887

64
h-index

9118

149
g-index

208
all docs

208
docs citations

208
times ranked

40673
citing authors

#	ARTICLE	IF	CITATIONS
1	Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 183-195.	4.6	585
2	Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e25803.	1.2	1
3	SARS-CoV-2 specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	24
4	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. <i>Journal of Infection</i> , 2022, 84, 675-683.	1.7	87
5	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350.	13.9	501
6	Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's COVID-19 Public Health Response. <i>Microbiology Spectrum</i> , 2022, 10, e0228921.	1.2	2
7	Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England. <i>PLoS ONE</i> , 2022, 17, e0262515.	1.1	4
8	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1532-1546.	13.9	1,709
9	Emergence of the delta variant and risk of SARS-CoV-2 infection in secondary school students and staff: Prospective surveillance in 18 schools, England. <i>EClinicalMedicine</i> , 2022, 45, 101319.	3.2	8
10	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
11	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e220-e234.	5.9	20
12	Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. <i>Transfusion Medicine</i> , 2021, 31, 167-175.	0.5	71
13	Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children. <i>Clinical and Experimental Immunology</i> , 2021, 204, 125-133.	1.1	4
14	Inactivated pandemic 2009 H1N1 influenza A virus human vaccines have different efficacy after homologous challenge in the ferret model. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 142-153.	1.5	5
15	Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24341.	1.2	22
16	Mass testing after a single suspected or confirmed case of COVID-19 in London care homes, April-May 2020: implications for policy and practice. <i>Age and Ageing</i> , 2021, 50, 649-656.	0.7	10
17	Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study. <i>Diagnostic and Prognostic Research</i> , 2021, 5, 4.	0.8	7
18	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 699-711.	5.2	122

#	ARTICLE	IF	CITATIONS
19	The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. <i>Eurosurveillance</i> , 2021, 26, .	3.9	10
20	Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective observational cohort study, England 2020. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100038.	3.0	30
21	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). <i>Lancet</i> , The, 2021, 397, 1459-1469.	6.3	557
22	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 349-359.	5.2	161
23	COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. <i>Lancet</i> , The, 2021, 397, 1725-1735.	6.3	658
24	Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. <i>International Journal of Epidemiology</i> , 2021, 50, 1124-1133.	0.9	124
25	Favipiravir-resistant influenza A virus shows potential for transmission. <i>PLoS Pathogens</i> , 2021, 17, e1008937.	2.1	23
26	SARS-CoV-2 infection and transmission in primary schools in England in June–December, 2020 (sKIDs): an active, prospective surveillance study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 417-427.	2.7	78
27	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 773-785.	5.2	78
28	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet</i> , The, 2021, 398, 223-237.	6.3	110
29	SARS-CoV-2 infection, antibody positivity and seroconversion rates in staff and students following full reopening of secondary schools in England: A prospective cohort study, September–December 2020. <i>EClinicalMedicine</i> , 2021, 37, 100948.	3.2	17
30	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e498-e506.	2.2	58
31	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594.	13.9	2,411
32	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e354-e365.	3.4	216
33	Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction. <i>Transfusion</i> , 2021, 61, 2837-2843.	0.8	29
34	Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England. <i>Journal of Infection</i> , 2021, 83, 573-580.	1.7	18
35	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624.	6.0	124
36	Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. <i>EClinicalMedicine</i> , 2021, 39, 101064.	3.2	116

#	ARTICLE	IF	CITATIONS
37	Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study. <i>Journal of Infection</i> , 2021, , .	1.7	6
38	Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England. <i>EClinicalMedicine</i> , 2021, 41, 101150.	3.2	8
39	Epidemiological and clinical characteristics of early COVID-19 cases, United Kingdom of Great Britain and Northern Ireland. <i>Bulletin of the World Health Organization</i> , 2021, 99, 178-189.	1.5	18
40	Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. <i>The Lancet Healthy Longevity</i> , 2021, 2, e811-e819.	2.0	54
41	Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016â€“2017 and 2017â€“2018 Influenza Seasons in the United Kingdom. <i>Clinical Infectious Diseases</i> , 2020, 70, 2505-2513.	2.9	13
42	Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillanceâ€”opportunities and challenges. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 622-629.	1.5	31
43	Clinical characteristics, predictors, and performance of case definitionâ€”Interim results from the WHO global respiratory syncytial virus surveillance pilot. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 647-657.	1.5	40
44	Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children. <i>Clinical and Experimental Immunology</i> , 2020, 199, 109-118.	1.1	6
45	Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. <i>Clinical Infectious Diseases</i> , 2020, 71, 2872-2879.	2.9	17
46	Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020. <i>EClinicalMedicine</i> , 2020, 26, 100533.	3.2	79
47	High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England. <i>EClinicalMedicine</i> , 2020, 28, 100597.	3.2	65
48	Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. <i>Eurosurveillance</i> , 2020, 25, .	3.9	5,865
49	Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016â€“17. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 671-677.	1.5	7
50	Increased risk of SARS-CoV-2 infection in staff working across different care homes: enhanced COVID-19 outbreak investigations in London care Homes. <i>Journal of Infection</i> , 2020, 81, 621-624.	1.7	74
51	Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England. <i>British Journal of General Practice</i> , 2020, 70, e890-e898.	0.7	51
52	Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. <i>Journal of Infection</i> , 2020, 81, 785-792.	1.7	36
53	COVID-19 in children: analysis of the first pandemic peak in England. <i>Archives of Disease in Childhood</i> , 2020, 105, 1180-1185.	1.0	152
54	Probable Vertical Transmission of SARS-CoV-2 Infection. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e257-e260.	1.1	32

#	ARTICLE	IF	CITATIONS
55	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. <i>Lancet Infectious Diseases</i> , 2020, 20, 1034-1042.	4.6	493
56	Human respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 638-646.	1.5	49
57	Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England. <i>Journal of Infection</i> , 2020, 81, 427-434.	1.7	31
58	Invasive <i>Mycobacterium chimaera</i> Infections and Heater—Cooler Devices in Cardiac Surgery. <i>Emerging Infectious Diseases</i> , 2020, 26, 632-632.	2.0	3
59	Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV. <i>Vaccine</i> , 2020, 38, 2660-2670.	1.7	6
60	Toward unified molecular surveillance of RSV: A proposal for genotype definition. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 274-285.	1.5	52
61	Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort. <i>Wellcome Open Research</i> , 2020, 5, 98.	0.9	24
62	Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort. <i>Wellcome Open Research</i> , 2020, 5, 98.	0.9	18
63	Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43,) Tj ETQq1 1 0,784314 rgBT /Over	0.9	35
64	Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43,) Tj ETQq0 0 0,rgBT /Overlock 10 T	0.9	60
65	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	0.9	81
66	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	0.9	122
67	Household transmission of seasonal coronavirus infections: Results from the Flu Watch cohort study. <i>Wellcome Open Research</i> , 2020, 5, 145.	0.9	7
68	Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e18606.	1.2	66
69	The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19773.	1.2	44
70	Nosocomial transmission of influenza: A retrospective cross-sectional study using next generation sequencing at a hospital in England (2012–2014). <i>Influenza and Other Respiratory Viruses</i> , 2019, 13, 556-563.	1.5	18
71	The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. <i>PLoS ONE</i> , 2019, 14, e0222381.	1.1	102
72	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. <i>Antiviral Research</i> , 2019, 163, 70-74.	1.9	8

#	ARTICLE	IF	CITATIONS
73	Serological surveillance of influenza in an English sentinel network: pilot study protocol. <i>BMJ Open</i> , 2019, 9, e024285.	0.8	23
74	Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing. <i>Journal of Virology</i> , 2019, 93, .	1.5	42
75	End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18. <i>Eurosurveillance</i> , 2019, 24, .	3.9	36
76	Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: Results from the Flu Watch cohort study. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 171-182.	1.5	43
77	Urgent challenges in implementing live attenuated influenza vaccine. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e25-e32.	4.6	46
78	The mechanism of resistance to favipiravir in influenza. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 11613-11618.	3.3	243
79	<i>Mycobacterium chimaera</i> infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1164-1170.	2.8	60
80	Estimating the burden on general practitioner services in England from increases in respiratory disease associated with seasonal respiratory pathogen activity. <i>Epidemiology and Infection</i> , 2018, 146, 1389-1396.	1.0	21
81	The burden of seasonal respiratory infections on a national telehealth service in England. <i>Epidemiology and Infection</i> , 2017, 145, 1922-1932.	1.0	13
82	The emergence of enterovirus D68 in England in autumn 2014 and the necessity for reinforcing enterovirus respiratory screening. <i>Epidemiology and Infection</i> , 2017, 145, 1855-1864.	1.0	9
83	Insidious Risk of Severe <i>Mycobacterium chimaera</i> Infection in Cardiac Surgery Patients. <i>Clinical Infectious Diseases</i> , 2017, 64, 335-342.	2.9	129
84	Antibody-based assay discriminates Zika virus infection from other flaviviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8384-8389.	3.3	161
85	Global outbreak of severe <i>Mycobacterium chimaera</i> disease after cardiac surgery: a molecular epidemiological study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1033-1041.	4.6	198
86	Can defective interfering RNAs affect the live attenuated influenza vaccine? – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1235-1236.	4.6	3
87	Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity. <i>Journal of Immunological Methods</i> , 2017, 449, 1-6.	0.6	25
88	Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?. <i>PLoS ONE</i> , 2016, 11, e0152310.	1.1	58
89	Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. <i>Journal of Infection and Public Health</i> , 2016, 9, 231-235.	1.9	36
90	Late Ebola virus relapse causing meningoencephalitis: a case report. <i>Lancet</i> , The, 2016, 388, 498-503.	6.3	291

#	ARTICLE	IF	CITATIONS
91	Cohort Profile: The Flu Watch Study. <i>International Journal of Epidemiology</i> , 2016, 46, dyv370.	0.9	22
92	The potential risks and impact of the start of the 2015â€“2016 influenza season in the <scp>WHO</scp> European Region: a rapid risk assessment. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 236-246.	1.5	16
93	Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. <i>Nature Immunology</i> , 2016, 17, 204-213.	7.0	148
94	Harmonizing influenza primary-care surveillance in the United Kingdom: piloting two methods to assess the timing and intensity of the seasonal epidemic across several general practice-based surveillance schemes. <i>Epidemiology and Infection</i> , 2015, 143, 1-12.	1.0	41
95	Natural T Cellâ€“mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1422-1431.	2.5	229
96	Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10473-10478.	3.3	198
97	Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. <i>Eurosurveillance</i> , 2015, 20, .	3.9	83
98	Self-sampling for community respiratory illness: a new tool for national virological surveillance. <i>Eurosurveillance</i> , 2015, 20, 21058.	3.9	19
99	Enhanced MERS Coronavirus Surveillance of Travelers from the Middle East to England. <i>Emerging Infectious Diseases</i> , 2014, 20, 1562-1564.	2.0	27
100	A Mouse Model for <i>Betacoronavirus</i> Subgroup 2c Using a Bat Coronavirus Strain HKU5 Variant. <i>MBio</i> , 2014, 5, e00047-14.	1.8	55
101	An H7N1 Influenza Virus Vaccine Induces Broadly Reactive Antibody Responses against H7N9 in Humans. <i>Vaccine Journal</i> , 2014, 21, 1153-1163.	3.2	51
102	Developments in the treatment of severe influenza. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 560-565.	1.3	17
103	Administration of AS03B-adjuvanted A(H1N1)pdm09 Vaccine in Children Aged ≥ 3 Years Enhances Antibody Response to H3 and B Viruses Following a Single Dose of Trivalent Vaccine One Year Later. <i>Clinical Infectious Diseases</i> , 2014, 58, 181-187.	2.9	9
104	Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 445-454.	5.2	341
105	Open source clinical science for emerging infections. <i>Lancet Infectious Diseases</i> , 2014, 14, 8-9.	4.6	82
106	Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. <i>Molecular Therapy</i> , 2014, 22, 233-238.	3.7	101
107	Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom. <i>Journal of Virology</i> , 2014, 88, 13269-13283.	1.5	84
108	London 2012 Olympic and Paralympic Games: public health surveillance and epidemiology. <i>Lancet</i> , 2014, 383, 2083-2089.	6.3	76

#	ARTICLE	IF	CITATIONS
109	Effectiveness of seasonal influenza vaccination during pregnancy in preventing influenza infection in infants, England, 2013/14. <i>Eurosurveillance</i> , 2014, 19, 20959.	3.9	68
110	Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. <i>Journal of Virology</i> , 2013, 87, 7790-7792.	1.5	1,012
111	Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2324-2331.	1.3	7
112	Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. <i>Epidemiology and Infection</i> , 2013, 141, 620-630.	1.0	50
113	Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03A-Adjuvanted H1N1 2009 Vaccine. <i>PLoS ONE</i> , 2013, 8, e47448.	1.1	10
114	Mortality Attributable to Influenza in England and Wales Prior to, during and after the 2009 Pandemic. <i>PLoS ONE</i> , 2013, 8, e79360.	1.1	36
115	Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 723-30.	0.4	11
116	Evolutionary Dynamics of Local Pandemic H1N1/2009 Influenza Virus Lineages Revealed by Whole-Genome Analysis. <i>Journal of Virology</i> , 2012, 86, 11-18.	1.5	101
117	Microbiological aspects of public health planning and preparedness for the 2012 Olympic Games. <i>Epidemiology and Infection</i> , 2012, 140, 2142-2151.	1.0	12
118	Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 240-248.	4.6	186
119	Seroprevalence of Influenza A(H1N1)pdm09 Virus Antibody, England, 2010 and 2011. <i>Emerging Infectious Diseases</i> , 2012, 18, 1894-7.	2.0	25
120	Improving influenza vaccine virus selection Report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. <i>Influenza and Other Respiratory Viruses</i> , 2012, 6, 142-152.	1.5	73
121	Fatal Cases of Influenza A(H3N2) in Children: Insights from Whole Genome Sequence Analysis. <i>PLoS ONE</i> , 2012, 7, e33166.	1.1	17
122	Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. <i>Eurosurveillance</i> , 2012, 17, 20290.	3.9	278
123	Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 91-101.	4.6	90
124	Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1) - Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 497-498.	4.6	1
125	Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infection in England and Scotland, 2009-2010. <i>Emerging Infectious Diseases</i> , 2011, 17, 1807-1815.	2.0	26
126	Evolutionary Pathways of the Pandemic Influenza A (H1N1) 2009 in the UK. <i>PLoS ONE</i> , 2011, 6, e23779.	1.1	34

#	ARTICLE	IF	CITATIONS
127	Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic. <i>Antiviral Research</i> , 2011, 90, 205-212.	1.9	14
128	Use of Antiviral Drugs to Reduce Household Transmission of Pandemic (H1N1) 2009, United Kingdom1. <i>Emerging Infectious Diseases</i> , 2011, 17, 990-999.	2.0	41
129	Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. <i>Epidemiology and Infection</i> , 2010, 138, 1531-1541.	1.0	73
130	Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. <i>Antiviral Research</i> , 2010, 86, 128-136.	1.9	16
131	Nucleic Acid Dipstick Test for Molecular Diagnosis of Pandemic H1N1. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3608-3613.	1.8	17
132	Estimating influenza vaccine effectiveness using routinely collected laboratory data. <i>Journal of Epidemiology and Community Health</i> , 2010, 64, 1062-1067.	2.0	69
133	Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. <i>Lancet, The</i> , 2010, 375, 1100-1108.	6.3	676
134	A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. <i>Health Technology Assessment</i> , 2010, 14, 193-334.	1.3	9
135	Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted pre-pandemic vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7962-7967.	3.3	242
136	Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children. <i>Clinical Infectious Diseases</i> , 2009, 48, 389-396.	2.9	160
137	Monitoring the emergence of community transmission of influenza A/H1N1 2009 in England: a cross sectional opportunistic survey of self sampled telephone callers to NHS Direct. <i>BMJ: British Medical Journal</i> , 2009, 339, b3403-b3403.	2.4	48
138	Personal Protective Equipment and Risk for Avian Influenza (H7N3). <i>Emerging Infectious Diseases</i> , 2009, 15, 59-62.	2.0	20
139	The Immunogenicity of a Cell-derived H7N1 Split Influenza Virion Vaccine in Mice. <i>Scandinavian Journal of Immunology</i> , 2009, 69, 576-578.	1.3	1
140	A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. <i>Influenza and Other Respiratory Viruses</i> , 2009, 3, 107-117.	1.5	33
141	Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. <i>Antiviral Therapy</i> , 2009, 14, 751-762.	0.6	71
142	Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007-08 Season. <i>Emerging Infectious Diseases</i> , 2009, 15, 552-560.	2.0	316
143	Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their families. <i>European Journal of Pediatrics</i> , 2008, 167, 395-399.	1.3	32
144	Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines- Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum- Given Concomitantly with Influenza Vaccine to High-Risk Elderly Individuals. <i>Journal of Infectious Diseases</i> , 2008, 198, 1317-1326.	1.9	83

#	ARTICLE	IF	CITATIONS
145	The Evolution of Norovirus, the "Gastric Flu". PLoS Medicine, 2008, 5, e42.	3.9	50
146	Linking syndromic surveillance with virological self-sampling. Epidemiology and Infection, 2008, 136, 222-224.	1.0	30
147	Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. Journal of Clinical Investigation, 2008, 118, 4036-4048.	3.9	299
148	SARS transmission in Vietnam outside of the health-care setting. Epidemiology and Infection, 2007, 135, 392-401.	1.0	26
149	Alterations in Receptor Binding Properties of Recent Human Influenza H3N2 Viruses Are Associated with Reduced Natural Killer Cell Lysis of Infected Cells. Journal of Virology, 2007, 81, 11170-11178.	1.5	52
150	Lessons from the 1918 influenza. Nature Biotechnology, 2007, 25, 433-434.	9.4	10
151	A sensitive retroviral pseudotype assay for influenza H5N1 neutralizing antibodies. Influenza and Other Respiratory Viruses, 2007, 1, 105-112.	1.5	142
152	Perspectives in interpandemic influenza. IDrugs: the Investigational Drugs Journal, 2007, 10, 861-4.	0.7	0
153	Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. Antimicrobial Agents and Chemotherapy, 2006, 50, 2395-2402.	1.4	333
154	Reply to Skowronski et al.. Journal of Infectious Diseases, 2006, 193, 900-901.	1.9	3
155	Subcellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein. Journal of General Virology, 2005, 86, 3303-3310.	1.3	76
156	First external quality assurance of antibody diagnostic for SARS-new coronavirus. Journal of Clinical Virology, 2005, 34, 22-25.	1.6	21
157	Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses. Antiviral Therapy, 2005, 10, 873-877.	0.6	55
158	Influenza among U.K. Pilgrims to Hajj, 2003. Emerging Infectious Diseases, 2004, 10, 1882-1883.	2.0	54
159	Restrictions to the Adaptation of Influenza A Virus H5 Hemagglutinin to the Human Host. Journal of Virology, 2004, 78, 502-507.	1.5	61
160	Epidemiological features of a new strain of the influenza A virus "influenza A (H1N2) circulating in England and its public health implications. Virus Research, 2004, 103, 53-54.	1.1	2
161	The inexact science of influenza prediction. Lancet, The, 2004, 363, 582-583.	6.3	16
162	Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network. Journal of Clinical Microbiology, 2003, 41, 742-750.	1.8	193

#	ARTICLE	IF	CITATIONS
163	Severe and unrecognised: pertussis in UK infants. Archives of Disease in Childhood, 2003, 88, 802-806.	1.0	244
164	Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir. Antimicrobial Agents and Chemotherapy, 2003, 47, 2264-2272.	1.4	276
165	Development of vaccines against common colds. British Medical Bulletin, 2002, 62, 99-111.	2.7	15
166	Human Metapneumovirus as a Cause of Community-Acquired Respiratory Illness. Emerging Infectious Diseases, 2002, 8, 897-901.	2.0	265
167	Current research on respiratory viral infections: Fourth International Symposium. Antiviral Research, 2002, 55, 227-278.	1.9	43
168	Experience with the clinical development of influenza vaccines for potential pandemics. Medical Microbiology and Immunology, 2002, 191, 197-201.	2.6	11
169	Developing vaccines against potential pandemic influenza viruses. International Congress Series, 2001, 1219, 751-759.	0.2	2
170	A single radial haemolysis assay for antibody to H5 haemagglutinin. International Congress Series, 2001, 1219, 761-766.	0.2	9
171	Update on influenza and other viral pneumonias. Current Opinion in Infectious Diseases, 2001, 14, 199-204.	1.3	7
172	Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplantation, 2001, 28, 775-781.	1.3	78
173	Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Research, 2001, 49, 147-156.	1.9	142
174	Diagnosis of Influenza in the Community. Archives of Internal Medicine, 2001, 161, 2116.	4.3	153
175	Influenza A antigen exposure selects dominant V α 217+ TCR in human CD8+ cytotoxic T cell responses. International Immunology, 2001, 13, 1373-1381.	1.8	53
176	Response to influenza immunisation during treatment for cancer. Archives of Disease in Childhood, 2001, 84, 496-500.	1.0	66
177	Population estimates of persons presenting to general practitioners with influenza-like illness, 1987-96: a study of the demography of influenza-like illness in sentinel practice networks in England and Wales, and in The Netherlands. Epidemiology and Infection, 2000, 124, 245-253.	1.0	50
178	Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. British Journal of Cancer, 2000, 82, 1261-1265.	2.9	173
179	Influenza surveillance in England and Wales: October 1999 to May 2000. Communicable Disease and Public Health / Phls, 2000, 3, 261-6.	0.3	9
180	Seroconversion after influenza vaccination in patients with lung cancer. British Journal of Cancer, 1999, 80, 219-220.	2.9	81

#	ARTICLE	IF	CITATIONS
181	The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands. <i>European Journal of Epidemiology</i> , 1999, 15, 467-473.	2.5	103
182	Active and passive immunisation against respiratory syncytial virus. , 1999, 9, 227-236.		11
183	Fifty years of influenza surveillance. <i>Communicable Disease and Public Health / Phls</i> , 1999, 2, 81-2.	0.3	0
184	Strain designation for influenza viruses. <i>Communicable Disease and Public Health / Phls</i> , 1999, 2, 157-9.	0.3	1
185	Influenza activity in England and Wales: October 1998 to June 1999. <i>Communicable Disease and Public Health / Phls</i> , 1999, 2, 273-9.	0.3	5
186	Molecular Epidemiology of Two Consecutive Outbreaks of Parainfluenza 3 in a Bone Marrow Transplant Unit. <i>Journal of Clinical Microbiology</i> , 1998, 36, 2289-2293.	1.8	81
187	Sentinel surveillance of influenza in Europe 1997-1998. <i>Eurosurveillance</i> , 1998, 3, 29-31.	3.9	11
188	Laboratory containment for influenza A H5N1 virus: level 2, level 3, or level 3+?. <i>Communicable Disease and Public Health / Phls</i> , 1998, 1, 71-2.	0.3	5
189	Influenza surveillance in England and Wales: October 1997 to June 1998. <i>Communicable Disease and Public Health / Phls</i> , 1998, 1, 244-51.	0.3	7
190	Response to influenza virus vaccination in vertical HIV infection. <i>Archives of Disease in Childhood</i> , 1997, 76, 215-218.	1.0	24
191	Influenza surveillance in England and Wales: October 1996 to June 1997. <i>Communicable Disease Report CDR Review</i> , 1997, 7, R212-9.	0.3	3
192	Influenza surveillance in England and Wales: October 1995 to June 1996. <i>Communicable Disease Report CDR Review</i> , 1996, 6, R163-9.	0.3	6
193	Influenza surveillance in England and Wales: October 1994 to June 1995. <i>Communicable Disease Report CDR Review</i> , 1995, 5, R200-4.	0.3	2
194	Parvovirus B19 outbreak on an adult ward. <i>Epidemiology and Infection</i> , 1994, 113, 345-353.	1.0	54
195	Antibody capture haemadherence tests for parvovirus B19-specific IgM and IgG. <i>Journal of Virological Methods</i> , 1993, 45, 27-37.	1.0	14